BeiGene ( (ONC) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
BeiGene’s stock has been under scrutiny due to a notable increase in insider selling, which has raised concerns despite the company’s strong sales performance and promising financial outlook. Analysts have adjusted their price targets following the impressive growth of zanubrutinib in the U.S. and Europe, along with BeiGene’s projected revenues and disciplined cost management. However, the insider selling has introduced mixed sentiments, impacting the stock’s movement.
More about BeiGene
YTD Price Performance: 47.72%
Average Trading Volume: 410,110
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $31.04B
For further insights into ONC stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.